Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To evaluate the antiviral efficacy as measured by sustained virologic response (SVR, defined as HCV RNA < LLoQ 24 weeks post-treatment) of 30 mg or 90 mg GS-5885 when given with GS-9451, tegobuvir and RBV for 12 or 24 weeks To evaluate the safety and tolerability of 30 mg or 90 mg GS-5885 when given with GS-9451, tegobuvir and RBV for 12 or 24 weeks
Critère d'inclusion
- Genotype 1 Hepatitis C Virus Infection